Use of FSH receptor ligands for diagnosis and therapy of cancer
a technology of fsh receptor and cancer, which is applied in the field of diagnostic imaging and therapy, can solve the problems of inability to differentiate cancer, common sampling errors, and inability to achieve satisfactory diagnostic results, and achieve the effect of high expression
Active Publication Date: 2014-07-22
INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1
View PDF11 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Unfortunately, the available tests can detect only those cancers large enough to be palpable, visible on ultrasound, or capable of elevating the serum level of prostate-specific antigen (PSA).
However, the utility of PSA tests is limited by their inability to differentiate cancer from clinically irrelevant, non-malignant conditions (benign prostatic hyperplasia, prostatitis, trauma, and urinary retention) [Stenman et al., 2005; Zhu et al., 2006].
Since only a small amount of prostate tissue is obtained by needle biopsy, sampling errors are common.
However, none of them is satisfactory for diagnostic purposes [Bradford et al., 2006].
Moreover, the data are questionable, because the molecular weight of the band detected by their antibodies does not correspond to the known size of FSHR, and could be therefore an unrelated protein which crossreacts with their antibody.
However, the authors fail to recognize that targeting FSHR expressed on the epithelial tissue prostate tumor is difficult, because FSHR ligands delivered to the blood cannot cross easily by themselves the endothelial barrier [Vu Hai et al., 2004].
No therapeutic or diagnostic method for targeting prostate tumors is so far available for clinical use.
However, it is not known so far if the peptide is suitable for human diagnostic or therapy.
In conclusion there are no validated alternative procedures for specific targeting of prostate tumor vasculature.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment Construction
[0032]Definitions
[0033]As used herein, the term “FSHR” denotes the receptor to which the methods of the invention apply. The follicle stimulating hormone receptor or FSH-receptor (FSHR) is a transmembrane receptor that interacts with the follicle stimulating hormone (FSH) and represents a G protein-coupled receptor (GPCR).
[0034]As used herein, the term > denotes also the antigen recognized by the anti FSHR antibody 323 (ATCC as CRL-2689™) and in particular the products of the FSHR gene.
[0035]The follicle stimulating hormone, a central hormone of mammalian reproduction, is produced mainly in the anterior pituitary gland and the classical target organs are the ovary and testis. In females, FSH stimulates follicular maturation and oestrogen production through aromatization of androgens [reviewed in Macklon and Fauser, 1998]. In males, FSH functions such as stimulation of Sertoli cell proliferation in immature testis and maintenance of qualitatively and quantitatively normal spermatogen...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
| Property | Measurement | Unit |
|---|---|---|
| molecular weight | aaaaa | aaaaa |
| molecular weight | aaaaa | aaaaa |
| molecular weight | aaaaa | aaaaa |
Login to View More
Abstract
The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells.
Description
CROSS-REFERENCE TO RELATED APPLICATION[0001]This application is the U.S. national stage application of International Patent Application No. PCT / EP2009 / 051931, filed Feb. 18, 2009, the disclosure of which is hereby incorporated by reference in its entirety, including all figures, tables and amino acid or nucleic acid sequences.FIELD OF THE INVENTION[0002]The present invention relates to diagnostic imaging and therapy and in particular to the diagnostic imaging and therapy of numerous types of cancer, by means of compositions which specifically target FSH Receptor expressed by blood endothelial cells and circulating blood cells.BACKGROUND OF THE INVENTION[0003]Cancer Diagnostics[0004]Microscopic evaluation of a tissue section taken from a tumor remains the golden standard for determining a diagnosis of cancer. Analysis of genomic DNA, transcribed genes and expressed proteins all add important information to the histological features detected in the microscope images. Tomorrow's diagno...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Patents(United States)
IPC IPC(8): A61K39/395A61K49/00
CPCA61K47/48261A61K47/48384G01N33/57492G01N33/57434C07K16/2869G01N2333/59A61K47/48561A61K47/48569A61K49/0002A61K47/48638A61K51/088A61K51/1072A61K47/6849A61K47/6851A61K47/6869A61P35/00
Inventor GHINEA, NICOLAERADU, AURELIAN
Owner INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)